Vaccines and Infectious Disease

The majority of the world’s leading Sponsors and CROs have made Meridian a preferred partner for their traditional and next-generation infectious disease programs. This is because Meridian provides a broad North American footprint to support rapid enrollment, even for seasonal studies involving specific cohorts (e.g., seniors, pediatrics, healthy).

As the largest member of the Platinum Research Network, Meridian provides access to more than 47 million patients globally. Meridian also offers a flexible clinical infrastructure to accommodate new technologies and novel approaches.

Meridian principal investigators have had their research published in prestigious industry journals, including Vaccine. These investigators are also sought after by Sponsors and CROs to provide counsel for vaccine-related protocol development.

Across all major and emerging indications, including anti-infectives and immunologics, Meridian supports research programs for drugs, medical devices, diagnostics, and combination products.